The latest update is out from Clene (CLNN).
On February 29, 2024, the Company revealed exciting clinical results for its CNM-Au8 30mg treatment at the prestigious ACTRIMS Forum, showcasing the potential of this new therapy in the VISIONARY-MS trial long-term extension. This announcement, expected to intrigue investors and those tracking advancements in MS treatment, was also officially released to the public through a detailed press statement.
For detailed information about CLNN stock, go to TipRanks’ Stock Analysis page.
